Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbbVie Inc (ABBV) vs Kinross Gold Corporation (KGC) Price & Performance

AbbVie IncTrade
Kinross Gold CorporationTrade

Price performance (Past 24H)

Key statistics

AbbVie Inc vs Kinross Gold Corporation — how do they compare? AbbVie Inc trades at $249.8 (market cap $441.94B), while Kinross Gold Corporation trades at $27.69 (market cap $32.29B). The key difference: AbbVie Inc is far larger — about 13.7× Kinross Gold Corporation's market cap, and AbbVie Inc pays the higher dividend (2.77%). Which is the better fit depends on your goals.

ABBVKGC
Market Cap
$441.94B$32.29B
Sector
HealthBasic Materials
52-Week High
$263.58$38.06
52-Week Low
$197.38$18.70
Enterprise Value
$506.19B$30.37B
Dividend Yield
2.77%0.59%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbbVie Inc

AbbVie (ABBV) trades at $247.91, up 0.76% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a 70.73% buy consensus highlight robust fundamentals, driven by Skyrizi and Rinvoq growth offsetting Humira declines. Positive news includes Phase 2 ovarian cancer data and institutional stake increases, reinforcing momentum.

Outlook remains positive with a $278.69 price target, though risks include patent cliffs and debt levels. Revenue growth and dividend stability offer appeal, but investors should monitor competitive pressures and regulatory developments for sustained performance.

Kinross Gold Corporation

KGC trades at $27.40, down 0.87% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 earnings of $0.71 per share, beating estimates, and maintains robust fundamentals with a P/E of 10.36 and net income margin of 37.52%. Recent news includes an S&P credit upgrade to 'BBB' and progress on the Lobo-Marte project, signaling operational strength.

The outlook is positive, driven by earnings beats, rising free cash flow, and a consensus price target of $37.20 offering ~36% upside. Risks include cost pressures, gold price volatility, and execution of growth projects. Analyst sentiment is bullish with 59% buy ratings, but investors should monitor Q3 2026 results for sustained momentum.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AbbVie Inc

AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

Read more on ABBV

About Kinross Gold Corporation

Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.

Read more on KGC